Yimitasvir

Summary

Yimitasvir (CHEMBL5095203) is a phase-3 clinical-stage small molecule; indicated across 2 conditions including chronic hepatitis c virus infection and hepatitis c virus infection.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Indications: 2 conditions
• Clinical trials: 6
• Chemistry: 855 Da · C49H58N8O6

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL5095203
Name	Yimitasvir
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	121427236
Molecular formula	C49H58N8O6
Molecular weight	855
InChIKey	CMLNPOWEANUBIB-XIGHHNHFSA-N

SMILES: CC(C)[C@@H](C(=O)N1CCC[C@H]1C2=NC3=C(N2)C=C(C=C3)C4=C5[C@H]6CC[C@H](C6)C5=C(C=C4)C7=CC=C(C=C7)C8=CN=C(N8)[C@@H]9CCCN9C(=O)[C@H](C(C)C)NC(=O)OC)NC(=O)OC

IUPAC name: methyl N-[(2S)-1-[(2S)-2-[5-[4-[(1R,8S)-6-[2-[(2S)-1-[(2S)-2-(methoxycarbonylamino)-3-methylbutanoyl]pyrrolidin-2-yl]-3H-benzimidazol-5-yl]-3-tricyclo[6.2.1.02,7]undeca-2,4,6-trienyl]phenyl]-1H-imidazol-2-yl]pyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl]carbamate

Also known as: DAG-181, DAG181, Yimitasvir, YIMITASVIR

Parent form; salt/anhydrous children: CHEMBL5095204

Patent coverage: 7 distinct patent families (18 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 17 (94%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
chronic hepatitis C virus infection	3	MONDO:0005354	EFO:0004220
hepatitis C virus infection	3	MONDO:0005231	EFO:0003047

Clinical trials

Total trials: 6.

Phase distribution

Phase	Trials
PHASE1	3
PHASE3	2
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT03487107	PHASE3	COMPLETED	Phase 3 Study of Yimitasvir Phosphate Capsules
NCT04155515	PHASE3	COMPLETED	A Phase III Study to Evaluate Efficacy and Safety of TG-2349 in Combination With DAG181 and RBV for HCV Type I Patients
NCT03458481	PHASE2	COMPLETED	Phase 2 Study of Yimitasvir Phosphate Capsules
NCT03462173	PHASE1	COMPLETED	The Safety, Tolerability and Pharmacokinetic Study of Yimitasvir in Healthy Adults Subjects
NCT03610880	PHASE1	COMPLETED	To Evaluate PK and Safety Profile of Oral MAD of Separately Using TG-2349, DAG181 or Combination in Healthy Chinese Volunteers
NCT04565171	PHASE1	COMPLETED	Pharmacokinetics of Yimitasvir Phosphate Capsule in Subjects With Normal Renal Function and ESRD

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).